The Q·Score Snapshot

Eli Lilly scores 8.2 out of 10, carrying a "Bullish" Q·Score label. The Q·Score aggregates fundamental signals — growth rates, profitability, valuation, and analyst sentiment — into a single composite reading; a score of 8.2 places LLY firmly in the upper tier of the stocks tracked on this platform. The score reflects the consistency and magnitude of the financial data points described below, not a recommendation of any kind.

Business at a Glance

Eli Lilly is a global pharmaceutical company headquartered in Indianapolis, Indiana, operating within the Healthcare sector. The company discovers, develops, and commercialises medicines across several therapeutic areas, with its most consequential recent growth driven by its GLP-1 receptor agonist franchise — most notably tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for obesity. That franchise has become one of the fastest-growing product lines in pharmaceutical history, and it is the primary engine behind the extraordinary revenue and earnings figures now appearing in Lilly's financials.

The Numbers That Stand Out

Revenue grew 55.5% year-over-year, a rate that is exceptional for a company already operating at this scale — most large-cap pharmaceutical peers grow in the low-to-mid single digits in a typical year. Earnings growth of 169.9% amplifies that revenue story, suggesting that incremental sales are flowing through to the bottom line with significant operating leverage. The net profit margin sits at 35%, meaning Lilly keeps $0.35 of every dollar of revenue as net income — a figure that compares favourably even within a sector known for high margins. Return on equity (ROE) of 107.5% — a measure of how much profit a company generates relative to shareholders' equity on the books — is an unusually high reading, partly a function of the company's capital structure but also reflective of its earnings power. Perhaps most striking from a consistency standpoint: Lilly has beaten analyst earnings-per-share (EPS) estimates in 100% of the quarters tracked in this dataset.

What Analysts Think

Of the 29 analysts currently covering LLY, 77% carry a positive rating on the stock — indicating that the majority of the professional analyst community leans constructive on the name. The consensus price target implies approximately 19% upside from the current price of $1,015.75, placing the aggregate analyst target in the vicinity of $1,209. It is worth noting that with a stock that has moved as dramatically as LLY has over recent years, individual price targets within that consensus vary widely, and the 23% of analysts without a positive rating reflects a meaningful dissenting view on valuation or execution risk.

The Bigger Picture

Within the Healthcare sector, Eli Lilly has become something of a singular data outlier — its growth metrics are running at rates more commonly associated with high-growth technology companies than with established pharmaceutical firms. The forward P/E of 22.9x — that is, the current stock price divided by the earnings analysts expect over the next twelve months — is notably moderate relative to the growth rate, a relationship sometimes described by analysts using the PEG ratio framework. Whether that relationship persists depends entirely on whether the GLP-1 commercial trajectory continues on its current path, faces competitive pressure, or encounters supply or regulatory headwinds — all variables the data alone cannot resolve.